Literature DB >> 30190918

Advantages of whole-genome sequencing for identification of tumor etiology and clinically actionable genomic aberrations: lessons from the Australian Melanoma Genome Project.

James S Wilmott1,2,1,2, Nicholas K Hayward1,3,1,3, Graham J Mann1,4,1,4, Richard A Scolyer1,2,5,1,2,5.   

Abstract

Entities:  

Keywords:  clinical utility; genome sequencing; genomics; melanoma; mutation

Year:  2017        PMID： 30190918      PMCID： PMC6094620          DOI： 10.2217/mmt-2017-0008

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


× No keyword cloud information.
  9 in total

Review 1.  The noncoding RNA revolution-trashing old rules to forge new ones.

Authors:  Thomas R Cech; Joan A Steitz
Journal:  Cell       Date:  2014-03-27       Impact factor: 41.582

Review 2.  Role of non-coding sequence variants in cancer.

Authors:  Ekta Khurana; Yao Fu; Dimple Chakravarty; Francesca Demichelis; Mark A Rubin; Mark Gerstein
Journal:  Nat Rev Genet       Date:  2016-01-19       Impact factor: 53.242

3.  Whole-genome landscapes of major melanoma subtypes.

Authors:  Nicholas K Hayward; James S Wilmott; Nicola Waddell; Peter A Johansson; Matthew A Field; Katia Nones; Ann-Marie Patch; Hojabr Kakavand; Ludmil B Alexandrov; Hazel Burke; Valerie Jakrot; Stephen Kazakoff; Oliver Holmes; Conrad Leonard; Radhakrishnan Sabarinathan; Loris Mularoni; Scott Wood; Qinying Xu; Nick Waddell; Varsha Tembe; Gulietta M Pupo; Ricardo De Paoli-Iseppi; Ricardo E Vilain; Ping Shang; Loretta M S Lau; Rebecca A Dagg; Sarah-Jane Schramm; Antonia Pritchard; Ken Dutton-Regester; Felicity Newell; Anna Fitzgerald; Catherine A Shang; Sean M Grimmond; Hilda A Pickett; Jean Y Yang; Jonathan R Stretch; Andreas Behren; Richard F Kefford; Peter Hersey; Georgina V Long; Jonathan Cebon; Mark Shackleton; Andrew J Spillane; Robyn P M Saw; Núria López-Bigas; John V Pearson; John F Thompson; Richard A Scolyer; Graham J Mann
Journal:  Nature       Date:  2017-05-03       Impact factor: 49.962

4.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

5.  TERT promoter mutations in familial and sporadic melanoma.

Authors:  Susanne Horn; Adina Figl; P Sivaramakrishna Rachakonda; Christine Fischer; Antje Sucker; Andreas Gast; Stephanie Kadel; Iris Moll; Eduardo Nagore; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

6.  Highly recurrent TERT promoter mutations in human melanoma.

Authors:  Franklin W Huang; Eran Hodis; Mary Jue Xu; Gregory V Kryukov; Lynda Chin; Levi A Garraway
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

7.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.

Authors:  Nicholas McGranahan; Andrew J S Furness; Rachel Rosenthal; Sofie Ramskov; Rikke Lyngaa; Sunil Kumar Saini; Mariam Jamal-Hanjani; Gareth A Wilson; Nicolai J Birkbak; Crispin T Hiley; Thomas B K Watkins; Seema Shafi; Nirupa Murugaesu; Richard Mitter; Ayse U Akarca; Joseph Linares; Teresa Marafioti; Jake Y Henry; Eliezer M Van Allen; Diana Miao; Bastian Schilling; Dirk Schadendorf; Levi A Garraway; Vladimir Makarov; Naiyer A Rizvi; Alexandra Snyder; Matthew D Hellmann; Taha Merghoub; Jedd D Wolchok; Sachet A Shukla; Catherine J Wu; Karl S Peggs; Timothy A Chan; Sine R Hadrup; Sergio A Quezada; Charles Swanton
Journal:  Science       Date:  2016-03-03       Impact factor: 47.728

8.  Deciphering signatures of mutational processes operative in human cancer.

Authors:  Ludmil B Alexandrov; Serena Nik-Zainal; David C Wedge; Peter J Campbell; Michael R Stratton
Journal:  Cell Rep       Date:  2013-01-10       Impact factor: 9.423

Review 9.  Mutational signatures: the patterns of somatic mutations hidden in cancer genomes.

Authors:  Ludmil B Alexandrov; Michael R Stratton
Journal:  Curr Opin Genet Dev       Date:  2013-12-29       Impact factor: 5.578
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.